Cargando…

Prediction of EGFR Mutation Status in Non–Small Cell Lung Cancer Based on Ensemble Learning

Objectives: We aimed to identify whether ensemble learning can improve the performance of the epidermal growth factor receptor (EGFR) mutation status predicting model. Methods: We retrospectively collected 168 patients with non–small cell lung cancer (NSCLC), who underwent both computed tomography (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feng, Youdan, Song, Fan, Zhang, Peng, Fan, Guangda, Zhang, Tianyi, Zhao, Xiangyu, Ma, Chenbin, Sun, Yangyang, Song, Xiao, Pu, Huangsheng, Liu, Fei, Zhang, Guanglei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271946/ https://www.ncbi.nlm.nih.gov/pubmed/35833032 http://dx.doi.org/10.3389/fphar.2022.897597

Ejemplares similares

In vivo accurate detection of the liver tumor with pharmacokinetic parametric images from dynamic fluorescence molecular tomography
por: Liu, Fei, et al.
Publicado: (2022)

PET/CT Based EGFR Mutation Status Classification of NSCLC Using Deep Learning Features and Radiomics Features
por: Huang, Weicheng, et al.
Publicado: (2022)

D2A U-Net: Automatic segmentation of COVID-19 CT slices based on dual attention and hybrid dilated convolution
por: Zhao, Xiangyu, et al.
Publicado: (2021)

A Multi-Classification Model for Predicting the Invasiveness of Lung Adenocarcinoma Presenting as Pure Ground-Glass Nodules
por: Song, Fan, et al.
Publicado: (2022)

Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China
por: Shu, Yamin, et al.
Publicado: (2022)

Case report: Concomitant EGFR mutation and ALK rearrangement in non-small cell lung cancer
por: Hu, Haoyue, et al.
Publicado: (2023)

Neoadjuvant targeted therapy for resectable EGFR-mutant non-small cell lung cancer: Current status and future considerations
por: Liu, Wenliang, et al.
Publicado: (2022)

Chinese Herbal Medicine Combined With First-Generation EGFR-TKIs in Treatment of Advanced Non-Small Cell Lung Cancer With EGFR Sensitizing Mutation: A Systematic Review and Meta-Analysis
por: Lu, Yan, et al.
Publicado: (2021)

Restricting Glutamine Uptake Enhances NSCLC Sensitivity to Third-Generation EGFR-TKI Almonertinib
por: Liu, Yaming, et al.
Publicado: (2021)

Ascertaining an Appropriate Diagnostic Algorithm Using EGFR Mutation-Specific Antibodies to Detect EGFR Status in Non-Small-Cell Lung Cancer
por: Jiang, Guiyang, et al.
Publicado: (2013)

Chinese Herbal Medicine Combined With EGFR-TKI in EGFR Mutation-Positive Advanced Pulmonary Adenocarcinoma (CATLA): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
por: Jiao, Lijing, et al.
Publicado: (2019)

Gossypol Inhibits Non-small Cell Lung Cancer Cells Proliferation by Targeting EGFR(L858R/T790M)
por: Wang, Yuwei, et al.
Publicado: (2018)

Association of EGFR Tyrosine Kinase Inhibitor Treatment With Progression-Free Survival Among Taiwanese Patients With Advanced Lung Adenocarcinoma and EGFR Mutation
por: Chen, Po-Yen, et al.
Publicado: (2021)

SH-1028, An Irreversible Third-Generation EGFR TKI, Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer
por: Han, Luwei, et al.
Publicado: (2021)

Survival Prediction of Patients Treated With Immune Checkpoint Inhibitors via KRAS/TP53/EGFR-Single Gene Mutation
por: Liu, Shui, et al.
Publicado: (2022)

A Radiogenomics Ensemble to Predict EGFR and KRAS Mutations in NSCLC
por: Moreno, Silvia, et al.
Publicado: (2021)

Recent Advancements of Monotherapy, Combination, and Sequential Treatment of EGFR/ALK-TKIs and ICIs in Non–Small Cell Lung Cancer
por: Liao, Dehua, et al.
Publicado: (2022)

Phenotype and Molecular Characterizations of 30 Children From China With NR5A1 Mutations
por: Song, Yanning, et al.
Publicado: (2018)

Case Report: Response to Almonertinib in a Patient With Metastatic NSCLC Resistant to Osimertinib due to Acquired EGFR L718Q Mutation
por: Shen, Gang, et al.
Publicado: (2021)

Experimental Study of Almonertinib Crossing the Blood-Brain Barrier in EGFR-Mutant NSCLC Brain Metastasis and Spinal Cord Metastasis Models
por: Zhang, Yuhan, et al.
Publicado: (2021)

Efficacy of immune checkpoint inhibitors in EGFR-Mutant NSCLC patients with EGFR-TKI resistance: A systematic review and meta-analysis
por: Qian, Xiaoyu, et al.
Publicado: (2022)

Antagonist Targeting microRNA-155 Protects against Lithium-Pilocarpine-Induced Status Epilepticus in C57BL/6 Mice by Activating Brain-Derived Neurotrophic Factor
por: Cai, Zhengxu, et al.
Publicado: (2016)

Apigenin Combined With Gefitinib Blocks Autophagy Flux and Induces Apoptotic Cell Death Through Inhibition of HIF-1α, c-Myc, p-EGFR, and Glucose Metabolism in EGFR L858R+T790M-Mutated H1975 Cells
por: Chen, ZiSheng, et al.
Publicado: (2019)

Detection of EGFR Mutations From Plasma of NSCLC Patients Using an Automatic Cartridge-Based PCR System
por: Heeke, Simon, et al.
Publicado: (2021)

Comparison of the efficacy and safety of first-line treatments for of advanced EGFR mutation-positive non-small-cell lung cancer in Asian populations: a systematic review and network meta-analysis
por: Chen, Wei, et al.
Publicado: (2023)

Locally advanced head and neck squamous cell carcinoma treatment efficacy and safety: a systematic review and network meta-analysis
por: Wang, Huanhuan, et al.
Publicado: (2023)

Phospholipase Cγ2 Signaling Cascade Contribute to the Antiplatelet Effect of Notoginsenoside Fc
por: Liu, Yingqiu, et al.
Publicado: (2018)

MoRF-FUNCpred: Molecular Recognition Feature Function Prediction Based on Multi-Label Learning and Ensemble Learning
por: Li, Haozheng, et al.
Publicado: (2022)

Feiyiliu Mixture sensitizes EGFR(Del19/T790M/C797S) mutant non-small cell lung cancer to osimertinib by attenuating the PRC1/Wnt/EGFR pathway
por: Shi, Jingjing, et al.
Publicado: (2023)

Mutations Status of Chemokine Signaling Pathway Predict Prognosis of Immune Checkpoint Inhibitors in Colon Adenocarcinoma
por: Lin, Anqi, et al.
Publicado: (2021)

Discovery of Potent EGFR Inhibitors With 6-Arylureido-4-anilinoquinazoline Derivatives
por: Li, Meng, et al.
Publicado: (2021)

Lysophosphatidic Acid–Induced EGFR Transactivation Promotes Gastric Cancer Cell DNA Replication by Stabilizing Geminin in the S Phase
por: Zhao, Haile, et al.
Publicado: (2021)

Fibrinogen is associated with EGFR mutation status and lymphatic metastasis in non-small cell lung cancer
por: Guan, Jian, et al.
Publicado: (2019)

Acacetin exerts antitumor effects on gastric cancer by targeting EGFR
por: Zhang, Guangtao, et al.
Publicado: (2023)

Cost-effectiveness analysis of toripalimab plus chemotherapy as the first-line treatment in patients with advanced non-small cell lung cancer (NSCLC) without EGFR or ALK driver mutations from the Chinese perspective
por: Zhou, Kexun, et al.
Publicado: (2023)

FGFC1 Selectively Inhibits Erlotinib-Resistant Non-Small Cell Lung Cancer via Elevation of ROS Mediated by the EGFR/PI3K/Akt/mTOR Pathway
por: Yan, Shike, et al.
Publicado: (2022)

Efficacy of brain radiotherapy plus EGFR-TKI for EGFR-mutated non-small cell lung cancer patients who develop brain metastasis
por: Wang, Wenxian, et al.
Publicado: (2018)

Association Between NR3C1 Mutations and Glucocorticoid Resistance in Children With Acute Lymphoblastic Leukemia
por: Liu, Haiyan, et al.
Publicado: (2021)

Folliculin Interacts with Rab35 to Regulate EGF-Induced EGFR Degradation
por: Zheng, Jianchao, et al.
Publicado: (2017)

The Application of Inorganic Nanoparticles in Molecular Targeted Cancer Therapy: EGFR Targeting
por: Sun, Meng, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dk0fn5lcasijlbfnrhponl48b5